dostarlimab-gxly

Immunotherapy drugs such as dostarlimab have a broad range of applications and are not limited to specific tumor types. Although currently approved for treating endometrial cancer and some dMMR solid tumors, it is possible that in the future it may be applicable for treating other types of cancers as well, including those beyond dMMR.

The article was received on August 12, 2022 and accepted on August 19, 2022.

The researchers at MSKCC were astonished and surprised by the unexpected outcome of their study. Dostarlimab, when used alone, successfully eradicated tumors and induced remission in all 12 participants. Remarkably, none of the participants required the radiation or chemotherapy that was initially planned for their treatment, and surgery was also unnecessary. This remarkable result is truly astounding.

Dostarlimab, marketed as Jemperli, is administered as a dostarlimab-gxly injection at a concentration of 500mg/10 ml. The price for each dose of this medication is $11,000.

Carrie Downey, who was diagnosed with colorectal cancer a year ago, received dostarlimab infusions for a period of six months. This drug specifically targets a variant of colorectal cancer and has already demonstrated impressive outcomes, eliminating the necessity for surgical procedures, radiotherapy, or chemotherapy.

The recommended dosage and potential side effects of dostarlimab are important considerations for its use in treating various cancers such as pancreatic cancer, ovarian cancer, fallopian tube cancer, non-small cell lung cancer (NSCLC), and small-cell lung cancer (SCLC).

The dostarlimab group had a progression-free survival rate of 36.1% (95% CI, 29.3 to 42.9) at 24 months, while the placebo group had a rate of 18.1% (95% CI, 13.0 to 23.9) (hazard ratio for progression or death, 0.64; 95% CI, 0.51 to 0.80; P<0.001).

Olaparib (Lynparza®) is a drug that specifically targets cancers with mutations in the BRCA genes. It functions by inhibiting the PARP molecule, preventing cancer cells from repairing their DNA and ultimately leading to their death.

Mehnert stated that antibody drug conjugates (ADCs) are an important area to monitor, with significant advancements in breast and bladder cancer, as well as lung and stomach cancer. ADCs are a method of specifically targeting cancer cells without the harmful effects of chemotherapy.

In this study, it was found that dostarlimab monotherapy showed consistent safety with the drug class and no new safety signals were observed. Additionally, the treatment demonstrated durable antitumor activity in patients with mismatch repair deficient and microsatellite instability-high advanced or recurrent solid tumors across multiple tumor types.

When used as the only form of treatment, the suggested dosage for dostarlimab is 500 mg every 3 weeks for 4 cycles, followed by 1000 mg every 6 weeks for all subsequent cycles.

Dostarlimab specifically acts on the cellular pathway involving the PD-1 receptor and its ligands, PD-L1 and PD-L2, present on immune cells. By binding to the PD-1 receptor, Dostarlimab inhibits its interaction with PD-L1 and PD-L2. This inhibition enables the activation of the PD-1 pathway-mediated immune response and promotes an antitumor immune response.

When chemotherapy is ineffective for patients with advanced stomach cancer and high microsatellite instability (MSI-H), pembrolizumab (Keytruda), nivolumab, and dostarlimab (Jemperli) can be considered as alternative treatment options. It is important to note that each type of immunotherapy may result in different side effects.

Jemperli (dostarlimab) is approved in the US for patients with recurrent or advanced solid tumors with dMMR, as confirmed by a US FDA-approved test, who have no other viable treatment options and have failed prior treatment.

Immunotherapy drugs such as dostarlimab have a broad range of applications and are not limited to specific tumor types. Although currently approved for treating endometrial cancer and some dMMR solid tumors, it is possible that in the future it may be applicable for treating other types of cancers as well, including those beyond dMMR.

Approximately 20% of patients experience adverse reactions when taking drugs such as dostarlimab, which are known as checkpoint inhibitors. These medications were administered every three weeks for a duration of six months, with each dose costing approximately $11,000.

Dostarlimab is a medication that can only be administered by a healthcare provider (HCP), meaning it can only be obtained through a physician. Unfortunately, NowPatient Rx Advantage Cards cannot be used to purchase HCP-administered medications at the physician’s office. However, there may be alternative methods to save money on your prescription.

The previous positive results, in which Jemperli demonstrated a higher tumor response rate and longer time to tumor progression compared to Keytruda, are further supported by the overall survival win.

Both Jemperli (dostarlimab) and Keytruda (pembrolizumab) are indicated for the treatment of advanced endometrial cancer that is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) in the second-line setting.

In February 2023, dostarlimab was granted full approval for the treatment of dMMR recurrent or advanced endometrial cancer. This approval applies to patients whose cancer has worsened after a platinum-based regimen in any setting and who are not suitable candidates for curative surgery or radiation.

Dostarlimab is prescribed for adults who have certain types of cancer that have not responded to previous treatments, have relapsed, or have spread and cannot be surgically removed. Your doctor will confirm if dostarlimab is suitable for your specific tumor type.

In February 2023, dostarlimab received regular approval from the FDA for patients in this population who have experienced disease progression or have received prior platinum-based treatment and are not eligible for curative radiation or surgery.

Dostarlimab underwent CDR grafting and affinity maturation to humanize it from a mouse antibody.

The mechanism of action involves inhibiting a specific protein in tumor cells, which enhances the immune system’s ability to combat the tumor cells and effectively reduces tumor growth. Administering cabozantinib and dostarlimab may potentially yield improved outcomes for patients with recurrent gynecologic cancer.

In the United States, the price of dostarlimab is approximately $11,000 per dose in the field of economics.

At present, dostarlimab has received FDA approval solely for the treatment of recurrent or advanced endometrial cancer and solid tumors with mismatch repair deficiency (dMMR).

PARP inhibitors belong to the category of targeted therapy, while monoclonal antibodies like dostarlimab are a form of immunotherapy. Dostarlimab can potentially enhance the body’s immune system to combat cancer by impeding the growth and spread of tumor cells.

Dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC) was approved by the Food and Drug Administration (FDA) on February 9, 2023. This approval is for adult patients with recurrent or advanced endometrial cancer who have a mismatch repair deficiency (dMMR), as confirmed by an FDA-approved test. The patients must have also experienced disease progression after receiving prior treatment containing platinum.